Rosenblatt analyst Hans Mosesmann reiterates Arteris (NASDAQ:AIP) with a Buy and maintains $21 price target.
BriaCell Images Confirm Robust Anti-Tumor Activity In Patient With “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular painHeavily